Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
Purpose The association between initial molecular response and longer-term outcomes with nilotinib was examined. Patients and Methods Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbaseline...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Journal of clinical oncology
Year: 2012, Jahrgang: 30, Heft: 35, Pages: 4323-4329 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2011.40.5217 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1200/JCO.2011.40.5217 Verlag, kostenfrei, Volltext: http://ascopubs.org/doi/10.1200/JCO.2011.40.5217 
|
| Verfasserangaben: | Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576449033 | ||
| 003 | DE-627 | ||
| 005 | 20220814164959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180618s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2011.40.5217 |2 doi | |
| 035 | |a (DE-627)1576449033 | ||
| 035 | |a (DE-576)506449033 | ||
| 035 | |a (DE-599)BSZ506449033 | ||
| 035 | |a (OCoLC)1341011868 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Branford, Susan |e VerfasserIn |0 (DE-588)1169778755 |0 (DE-627)1035883791 |0 (DE-576)512242151 |4 aut | |
| 245 | 1 | 0 | |a Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib |c Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller |
| 264 | 1 | |c 2012 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online ahead of print at www.jco.org on October 29, 2012 | ||
| 500 | |a Gesehen am 18.06.2018 | ||
| 520 | |a Purpose The association between initial molecular response and longer-term outcomes with nilotinib was examined. Patients and Methods Patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase from the phase II nilotinib registration study with available postbaseline BCR-ABL1 transcript assessments were included (N = 237). Results BCR-ABL1 transcript levels (International Scale [IS]) at 3 months correlated with complete cytogenetic response (CCyR) by 24 months. Patients with BCR-ABL1 (IS) of > 1% to ≤ 10% at 3 months with nilotinib had higher cumulative incidence of CCyR by 24 months than patients with BCR-ABL1 (IS) of > 10% (53% v 16%). BCR-ABL1 (IS) at 3 months predicted major molecular response (MMR) by 24 months. Cumulative incidence of MMR by 24 months for patients with BCR-ABL1 (IS) of > 0.1% to ≤ 1%, > 1% to ≤ 10%, and > 10% was 65%, 27%, and 9%, respectively. These differences were observed for patients with or without baseline BCR-ABL1 mutations and for those with imatinib resistance or intolerance. Estimated event-free survival (EFS) rates at 24 months decreased with higher transcript levels at 3 months; patients with BCR-ABL1 (IS) of ≤ 1% had an estimated 24-month EFS rate of 82%, compared with 70% for patients with BCR-ABL1 (IS) of > 1% to ≤ 10% and 48% for patients with BCR-ABL1 (IS) of > 10%. Conclusion Patients with BCR-ABL1 (IS) of > 10% at 3 months had a lower cumulative incidence of CCyR and MMR and lower rates of EFS versus patients with BCR-ABL1 (IS) of ≤ 10%. Prospective studies may determine whether close monitoring or alternative therapies are warranted for patients with minimal initial molecular response. | ||
| 700 | 1 | |a Müller, Martin Christian |d 1972- |e VerfasserIn |0 (DE-588)121360296 |0 (DE-627)705409236 |0 (DE-576)181482819 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 30(2012), 35, Seite 4323-4329 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib |
| 773 | 1 | 8 | |g volume:30 |g year:2012 |g number:35 |g pages:4323-4329 |g extent:7 |a Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Branford, Susan |t Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib |d 2012 |w (DE-627)1447642732 |w (DE-576)377642738 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.2011.40.5217 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://ascopubs.org/doi/10.1200/JCO.2011.40.5217 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180618 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 121360296 |a Müller, Martin Christian |m 121360296:Müller, Martin Christian |d 60000 |d 61200 |e 60000PM121360296 |e 61200PM121360296 |k 0/60000/ |k 1/60000/61200/ |p 13 |y j | ||
| 999 | |a KXP-PPN1576449033 |e 301285326X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"recId":"1576449033","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Published online ahead of print at www.jco.org on October 29, 2012","Gesehen am 18.06.2018"],"title":[{"title":"Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib","title_sort":"Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Branford, Susan","given":"Susan","family":"Branford"},{"roleDisplay":"VerfasserIn","display":"Müller, Martin Christian","role":"aut","family":"Müller","given":"Martin Christian"}],"relHost":[{"id":{"zdb":["2005181-5"],"eki":["313116962"],"issn":["1527-7755"]},"origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedDisp":"1983-","dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology"}],"part":{"pages":"4323-4329","issue":"35","year":"2012","extent":"7","volume":"30","text":"30(2012), 35, Seite 4323-4329"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"pubHistory":["1.1983 -"],"language":["eng"],"corporate":[{"display":"American Society of Clinical Oncology","roleDisplay":"Herausgebendes Organ","role":"isb"}],"recId":"313116962","disp":"Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With NilotinibJournal of clinical oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"]}],"physDesc":[{"extent":"7 S."}],"id":{"doi":["10.1200/JCO.2011.40.5217"],"eki":["1576449033"]},"origin":[{"dateIssuedDisp":"2012","dateIssuedKey":"2012"}],"name":{"displayForm":["Susan Branford, Dong-Wook Kim, Simona Soverini, Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, and Martin C. Müller"]}} | ||
| SRT | |a BRANFORDSUINITIALMOL2012 | ||